SCHEMBL24254528

SCHEMBL24254528

CN(C)S(=O)(=O)c1ccc(NCc2ccccc2)c(N)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.50
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
POLB P06746 2/20 0.46
PKM P14618 1/20 0.46
KDM4E B2RXH2 2/20 0.45
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA9 Q16790 1/20 0.44
LMNA P02545 3/20 0.44
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
TNF P01375 1/20 0.43
NOD1 Q9Y239 1/20 0.43
MAPT P10636 3/20 0.43
TP53 P04637 3/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13374030 0.85 GLA (0.49) ALDH1A1MEN1KMT2ACA12CA1
SCHEMBL14074467 0.81 NAMPT (0.44) ALDH1A1MEN1KMT2APKMCA12
SCHEMBL16489598 0.78 ALDH1A1 (0.47) ALDH1A1MEN1KMT2APOLBKDM4E
SCHEMBL13462383 0.76 ALDH1A1 (0.51) ALDH1A1MEN1KMT2APOLBPKM
SCHEMBL13962995 0.76 ALDH1A1 (0.46) ALDH1A1MEN1KMT2APOLBPKM
SCHEMBL1646176 0.75 POLB (0.51) ALDH1A1POLBPKMKDM4ELMNA
SCHEMBL22747085 0.74 ALDH1A1 (0.43) ALDH1A1POLBKDM4ELMNANPC1
SCHEMBL4966969 0.73 NAMPT (0.55) MEN1KMT2APOLBPKMLMNA
SCHEMBL24254589 0.73 HDAC6 (0.43) ALDH1A1MEN1KMT2AKDM4EMAPT
SCHEMBL1040774 0.73 HDAC6 (0.68) MEN1KMT2APOLBKDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230271918-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-31 US disclosed
US-20230271918-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-31 US disclosed
WO-2022035804-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230271918-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 USP28, USP30, USP1 ALDH1A1 1387/4885MEN1 3058/4885KMT2A 326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.